Sale

FITC-Compatible Human CD19 Protein (CD1-HM119F)

FITC-Compatible Human CD19 Protein (CD1-HM119F)

FITC-Compatible Human CD19 Protein (CD1-HM119F)

$810.00$1,800.00

In stock

$810.00$1,800.00

KACTUS Biosystems FITC-Compatible Human CD19 Protein (CD1-HM119F) (catalog No. CD1-HM119F) is expressed from HEK293 with His tag at the C-Terminus.It contains Pro20-Lys291.

SKU: CD1-HM119F Categories: ,
Clear
View cart
Order Offline:
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Catalog No. CD1-HM119F
Product NameFITC-Compatible Human CD19 Protein (CD1-HM119F)
Supplier Name KACTUS Biosystems
Brand Name KACTUS Biosystems
Synonyms CD19; B4; CVID3; Leu-12; MGC12802
Species Human
Source HEK293
Accession P15391-1
Product Tag C-His
Biotinylated no
Exact Sequence Pro20-Lys291
Molecular Weight The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.
Form Liquid
Formulation Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Purity > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
Endotoxin Less than 1 EU per μg by the LAL method.
Shipping Shipped with dry ice.
Stability & Storage Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Note Products will be shipped from the warehouse in Massachusetts. Promotion is running from time to time. Welcome to send a request for quote to message@sydlabs.com.
Order Offline Syd Labs, Inc. 4 Avenue E, Hopkinton, MA 01748 USA. Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com

Description

CD1-HM119F: FITC-Compatible Human CD19 Protein (CD1-HM119F)

CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.

Please remember our product information: FITC-Compatible Human CD19 Protein (CD1-HM119F) catalog number: CD1-HM119F KACTUS Biosystems

No more offers for this product!